Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: Review of the literature and future perspectives.
Sign Up to like & getrecommendations! Published in 2019 at "Critical reviews in oncology/hematology"
DOI: 10.1016/j.critrevonc.2019.102820
Abstract: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) improved clinical outcome compared to chemotherapy in EGFR mutated advanced non-small cell lung cancer (NSCLC) patients. Nonetheless, acquired resistance develops within 10-14 months and 20-30% of EGFR-mutated… read more here.
Keywords: egfr tkis; egfr mutated; combination egfr; tkis chemotherapy ... See more keywords